News | News By Subject | News by Disease News By Date | Search News

Muscular Dystrophy News Articles

Get Our FREE
Industry eNewsletter
Top Breaking News
Sarepta (SRPT)’s Exondys 51 Saga Continues as More Details About FDA’s Criticism Uncovered     8/22/2017
PTC Therapeutics (PTCT) Buys Marathon Pharma's Controversial $89,000-Per-Year DMD Drug for $190 Million     3/16/2017
Catabasis (CATB) Plunges on DMD Drug Trial Failure     2/1/2017
JPM17: Sarepta (SRPT)'s New Numbers Impress Investors, Stock Gained $300 Million Overnight     1/11/2017
Humana (HUM) to Cover Sarepta (SRPT)'s Controversial DMD Drug But There's a Catch     10/27/2016
Sarepta (SRPT) Gets No Love From the FDA's New Drugs Director     10/21/2016
PTC Therapeutics (PTCT) Tanks After the FDA Denies DMD Drug Translarna Again     10/17/2016
Watch Out, Ionis Pharma (IONS): Could This Little Biotech’s Experimental SMA Treatment Be a Threat?     10/17/2016
Sarepta (SRPT) Goes for a New DMD Combo With New $562 Million+ Deal With Summit Therapeutics     10/4/2016
Saga Continues for Sarepta (SRPT) as FDA Head Calls for Retraction of 'Misleading' 2013 Study     9/23/2016
Victory at Last! Sarepta (SRPT) Stock Doubles as the FDA Finally Approves DMD Drug     9/20/2016
Turn the Page: Sarepta (SRPT) Stock Pops on Rumors DMD Drug Naysayer Leaves the FDA     9/15/2016
Sarepta (SRPT)’s Duchene Muscular Dystrophy Drug: Evaluating the Placebo Effect     8/19/2016
Sarepta (SRPT) Stock Surges After Government Website Indicates Firm is Recruiting for Phase III Study     8/5/2016
FDA Hits DMD Drugmaker Santhera (SANN.SW) With Lengthy Delay     7/14/2016

News from Around the Web
PTC Therapeutics (PTCT)'s New $35,000 Price Tag For MD Drug Draws Criticism And Doubt     5/9/2017
Can Sarepta (SRPT) Continue To Live Up To The DMD Hype?     5/8/2017
More Senators Demand Answers From Marathon Pharma's CEO And His Pricey DMD Drug     3/6/2017
PTC Therapeutics (PTCT) Wants a Slice of Sarepta (SRPT)'s DMD Pie, Says Rejected Drug May Help Some Patients     10/7/2016
After Sarepta (SRPT)'s Win, BioMarin (BMRN) Wants a Piece of the Action Too     9/23/2016
Approving A Muscular Dystrophy Drug Exposes A Civil War At The FDA     9/20/2016
Approving Sarepta (SRPT)'s DMD Drug Could Force FDA To Get Creative     5/26/2016
Robotic Arm For Duchenne Patients Developed, University of Twente Reveals     1/25/2016
"Ringo The Dog" Helps Find Potential New Therapy For Muscular Dystrophy     11/18/2015
Scientists Make Diseased Cells Synthesize Their Own Drug, The Scripps Research Institute Reveals     9/4/2014
Viagra And Cialis Could Help Treat Duchenne Muscular Dystrophy, Cedars--Sinai Heart Institute Study     5/8/2014
What The Delay Of A Promising Muscular Dystrophy Drug Means For Patients, Investors And All Of Biotech     11/13/2013
Double Gene Flaws Lead to Rare Muscular Dystrophy, University of Rochester and Fred Hutchinson Cancer Research Center Study     11/14/2012
New Muscular Dystrophy Treatment Offers Hope, North Shore-Long Island Jewish Research Institute Study     3/24/2011
Human Protein Improves Muscle Function of Muscular Dystrophy in Mice, Brown University Study     12/28/2010

Press Releases
Phrixus Pharmaceuticals Announces Phase II Clinical Trial Of Poloxamer 188 NF In Non-Ambulatory Patients With Duchenne Muscular Dystrophy     9/14/2017
Phrixus Pharmaceuticals Announces The First Patient With Duchenne Muscular Dystrophy (DMD) To Meet The 15-Month Mark On Carmeseal-MD (Poloxamer 188 NF)     9/13/2017
First Patients Enrolled In UK’s Early Access To Medicines Scheme For Santhera (SANN.SW)a’s Raxone In Duchenne Muscular Dystrophy (DMD)     9/12/2017
Biophytis Clinical Stage Drug-Candidate Sarconeos Demonstrates Efficacy In Preclinical Models Of Duchenne Muscular Dystrophy     9/8/2017
Sarepta (SRPT) Announces Positive Results In Its Study Evaluating Gene Expression, Dystrophin Production, And Dystrophin Localization In Patients With Duchenne Muscular Dystrophy (DMD) Amenable To Skipping Exon 53 Treated With Golodirsen (SRP-4053)     9/6/2017
Sarepta (SRPT) Announces Its Partner, Genethon, Published New Micro-Dystrophin Gene Therapy Data In Nature Communications     7/27/2017
Clinigen And Sarepta (SRPT) Launch A Managed Access Program To Treat Patients With Duchenne Muscular Dystrophy Amenable To Exon 51 Skipping     7/19/2017
Santhera (SANN.SW)'s Raxone Receives First Positive EAMS Scientific Opinion From UK's MHRA In Duchenne Muscular Dystrophy     6/22/2017
Santhera (SANN.SW)’s Raxone Receives First Positive EAMS Scientific Opinion From UK’s MHRA In Duchenne Muscular Dystrophy     6/22/2017
Sarepta (SRPT) And Genethon Announce A Gene Therapy Research Collaboration For The Treatment Of Duchenne Muscular Dystrophy     6/21/2017
Solid Biosciences Strengthens Leadership Team To Advance Programs For Duchenne Muscular Dystrophy     6/7/2017
CD Access To Provide Special Access Program For Duchenne Muscular Dystrophy Patients In Canada     6/1/2017
Summit Therapeutics Completes Enrollment Of Phaseout DMD, A Phase II Clinical Trial Of Ezutromid In Patients With DMD     5/15/2017
Biophytis: First Patient-In In The United States And Opening Of 2 Clinical Centers For The SARA-OBS Study On Sarcopenia     5/11/2017
GTx, Inc. (GTXI) Announces Results From Preclinical Studies Of Sarms In Duchenne Muscular Dystrophy Models Published In Human Molecular Genetics     5/3/2017